Stockscreener 앱 받기
1.355
2.52%
-0.035
시간 외 거래:
1.36
0.005
+0.37%
전일 마감가:
$1.39
열려 있는:
$1.34
하루 거래량:
659.32K
Relative Volume:
0.39
시가총액:
$99.82M
수익:
-
순이익/손실:
$-292.19M
주가수익비율:
-0.2985
EPS:
-4.54
순현금흐름:
$-208.41M
1주 성능:
-23.01%
1개월 성능:
-34.54%
6개월 성능:
-59.55%
1년 성능:
-90.61%
1일 변동 폭
$1.34
$1.41
1주일 범위
$1.34
$2.015
52주 변동 폭
$1.34
$16.21
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
명칭
Zentalis Pharmaceuticals Inc
전화
(858) 263-4333
주소
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
ZNTL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
1.355 | 99.82M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-12 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2024-06-20 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-06-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-06-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | 다운그레이드 | Wedbush | Neutral → Underperform |
| 2024-06-18 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-11-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | 개시 | Cowen | Outperform |
| 2022-04-06 | 개시 | Wells Fargo | Overweight |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-09-29 | 개시 | Oppenheimer | Outperform |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-01-20 | 개시 | Wedbush | Outperform |
| 2020-09-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-08-27 | 개시 | H.C. Wainwright | Buy |
| 2020-04-28 | 개시 | Guggenheim | Buy |
| 2020-04-28 | 개시 | Jefferies | Buy |
| 2020-04-28 | 개시 | Morgan Stanley | Overweight |
| 2020-04-28 | 개시 | SVB Leerink | Outperform |
모두보기
Zentalis Pharmaceuticals Inc 주식(ZNTL)의 최신 뉴스
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Zentalis Strengthens Team with $194,600 in Equity Incentives - Stock Titan
Virtu Financial LLC Buys Shares of 24,973 Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Leerink Partnrs Issues Pessimistic Outlook for ZNTL Earnings - Defense World
What is HC Wainwright’s Forecast for ZNTL Q1 Earnings? - Defense World
Leerink Partnrs Has Pessimistic Outlook of ZNTL Q1 Earnings - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Position Lifted by Charles Schwab Investment Management Inc. - Defense World
Wedbush Reiterates Neutral Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals: Hold Rating Amid Clinical Progress and Financial Uncertainty - TipRanks
Bank of New York Mellon Corp Sells 10,375 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals Reports Progress and Financials - TipRanks
Stifel maintains Buy on Zentalis stock with $9 target By Investing.com - Investing.com Canada
H.C. Wainwright sets $10 target for Zentalis shares, maintains Buy By Investing.com - Investing.com Canada
Zentalis Pharmaceuticals Inc Reports Annual EPS of -$2.33, Excee - GuruFocus
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates - GlobeNewswire
Zentalis Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Zentalis Pharmaceuticals Inc Files For Mixed Shelf Of Up To $250 MillionSEC Filing - Marketscreener.com
Zentalis Breakthrough: 35% Response Rate in Ovarian Cancer Trial Wins FDA Fast Track - Stock Titan
Zentalis Pharmaceuticals to Present Multiple Posters at the - GlobeNewswire
Major Cancer Breakthrough: Zentalis Reveals New Azenosertib Data Across Multiple Tumor Types - Stock Titan
Zentalis Pharmaceuticals Inc expected to post a loss of 71 cents a shareEarnings Preview - TradingView
Zentalis pharmaceuticals director Luke Walker buys $24,966 in stock - MSN
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Earns Buy Rating from HC Wainwright - The AM Reporter
H.C. Wainwright maintains $10 target on Zentalis stock By Investing.com - Investing.com Canada
Zentalis Highlights Promising Azenosertib Data at SGO 2025 - TipRanks
Zentalis Pharmaceuticals Presents Updated Clinical Data at - GlobeNewswire
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer - MarketScreener
Zentalis Announces Updated Clinical Data From Part 1b Of DENALI Trial Of Azenosertib In PROC - Nasdaq
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer - TradingView
Breakthrough: Zentalis Drug Achieves 35% Response Rate Against Hard-to-Treat Ovarian Cancer - Stock Titan
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Has Been Trading Down. What Are The Prospects For The Future? - stocksregister.com
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of “Hold” from Brokerages - Defense World
ZNTL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Zentalis Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm! - ACCESS Newswire
How Zentalis Is Attracting Talent: Inside Their Latest Employee Compensation Package - StockTitan
Zentalis Pharmaceuticals Announces Multiple Data - GlobeNewswire
Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer - The Manila Times
Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer - Yahoo Finance
A company insider recently bought 20,000 shares of Zentalis Pharmaceuticals Inc [ZNTL]. Should You Buy? - Knox Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc.ZNTL - PR Newswire
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Can Zentalis' Novel Cancer Drug Pipeline Impress at Two Elite Healthcare Conferences? - StockTitan
Zentalis Pharmaceuticals (ZNTL) Projected to Post Quarterly Earnings on Tuesday - The AM Reporter
Zentalis stock price target cut to $10 by H.C. Wainwright - MSN
Zentalis pharmaceuticals officer sells $24,590 in stock - MSN
Zentalis Pharmaceuticals (ZNTL): Among Cheapest Stocks Insiders Are Buying Recently - Yahoo Finance
Savant Capital LLC Acquires New Shares in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis stock plunges to 52-week low, hits $2.16 - MSN
Zentalis Pharmaceuticals' chief medical officer acquires $45,656 in stock - MSN
Zentalis Pharmaceuticals Inc (ZNTL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
자본화:
|
볼륨(24시간):